Research to better understand and treat cancers and benign hematologic diseases
Translating VICC laboratory research into therapies to help people with cancer
State-of-the-art patient care and personalized cancer therapy
Clinical trials, including Phase I drug development with subsequent Phase II and Phase III testing
Training future hematology and oncology doctors and researchers
Cancer chemotherapy, pharmacology, and biological therapy with an emphasis on solid tumors
Treating bleeding and coagulation disorders, anemia and other disorders of blood
Committed to hematologic and oncologic care
Our clinical faculty see patients at the Vanderbilt-Ingram Cancer Center (a National Cancer Institute-designated Comprehensive Cancer Center), the Henry-Joyce Cancer Clinic and Clinical Research Center, multiple locations in middle Tennessee and the Vanderbilt University Hospital.
The Division of Hematology and Oncology looks forward to further expansion of its clinical enterprise, increasing availability of care for rare and common cancers and blood diseases, and offering cutting-edge therapeutics on multiple phase one, two and three trials. Additional plans are underway to expand the division’s laboratory presence with intentional growth of translational research, and to establish new relationships with key pharmaceutical partners to advance research that will lead to further improvements in the treatments for patients with benign and malignant diseases.
Research from lab to clinic
Our research faculty members continue to build on historical strengths while charting the way for new opportunities in prevention and treatment with an emphasis on bringing new treatment therapies from the laboratory to the clinic as quickly and safely as possible.
Top-ranked cancer care
We have met strict clinical and scientific requirements, and we are proud to be consistently ranked among the best places for cancer care by U.S. News and World Report.
Director, Division of Hematology and Oncology
Department of Medicine
Jordan Berlin, MD, is the Ingram Professor of Cancer Research, Department of Medicine, and Director, Division of Hematology Oncology, at Vanderbilt University Medical Center.
Dr. Berlin has practiced medicine for three decades and has specialized in treating patients with gastrointestinal cancers with particular interest in pancreatic cancer. He has advanced cancer care by leading numerous clinical trials, authoring research studies in prestigious medical journals and, most importantly, mentoring physicians in their careers.
Dr. Berlin completed medical school at the University of Illinois College of Medicine followed by a residency in internal medicine at the University of Cincinnati Hospital and fellowship training in hematology and oncology at the University of Wisconsin Hospital and Clinics.
Section Leaders, Division of Hematology and Oncology
The Division of Hematology and Oncology is arranged into two sections, Solid Tumor Oncology and Malignant Hematology and Stem Cell Transplantation.
Within each section, we have faculty that are laboratory-based researchers, clinicians who see patients at the Henry-Joyce Cancer Clinic and other sites in middle Tennessee and faculty who do both laboratory-based research and are clinicians. Because we recognize the importance of research in the clinical setting as well as in laboratories, our clinicians are involved in clinical research.
Solid Tumor Oncology Section Chief - Douglas Johnson, MD, MSCI
Malignant Hematology and Stem Cell Transplantation Section Chief - Michael R. Savona, MD